Merck KGaA subsidiary nabs first-of-its-kind declination letter from DOJ

The DOJ said the business proactively disclosed information about a scheme by an insider and others to export sensitive biochemicals to China.

The US Department of Justice (DOJ) has said it won’t bring charges against life-sciences and electronics company Merck KGaA’s North American unit, MillmoreSigma, for proactively disclosing details about a scheme by a company insider and others to export sensitive biochemicals to China.

But two of the men

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in